Clinical Protocol Writing Software: A Buyer’s Guide

Assyro publishes this guide, and its first-place recommendation is our editorial preference. The same evidence gates apply to every candidate. This is a documentary shortlist based on official materials checked September 14, 2026; we did not run these products or measure their drafting accuracy. An unknown must-have remains unresolved even when the vendor is Assyro.

This guide is for medical writing, clinical development, and regulatory operations teams choosing software to turn agreed study information into a reviewable protocol and maintain it through amendments. The decisive distinction is between software that summarizes a protocol you already have and software that creates and maintains the controlled document your team needs.

Shortlist by the workflow you need to change

The commercial candidates below cover different starting points. They are included for an explicitly documented protocol workflow or, in Assyro’s case, a conditional role connecting document preparation to submissions. This is not an exhaustive market ranking.

Keep a fifth option as your baseline: a controlled writing process using the TransCelerate Common Protocol Template. A template is not an automated authoring platform, but it helps establish what your team can already accomplish before buying one.

Separate writing assistance from study-design authority

Give prospective vendors a concrete output contract: “Using these approved sources, produce a protocol draft in our chosen structure, show where the content came from, preserve unresolved decisions, and demonstrate controlled revision and export.” That is materially different from asking a system to invent a plausible study.

Three activities need separate acceptance decisions:

1. Study design: deciding the scientific question, population, endpoints, intervention, assessments, and analysis approach. Software may organize or suggest options; qualified sponsor personnel must evaluate them.
2. Protocol authoring: expressing approved decisions, organizing sections, managing references, and maintaining consistency through review.
3. Amendment implementation: assessing an approved change’s impact on related documents and trial operations, then managing the necessary reviews and implementation steps.

A tool can be useful at the second activity without owning the first or completing the third. An authoring demonstration should make those boundaries visible. If a source omits a decision, the resulting draft should expose the gap instead of presenting a model-generated choice as sponsor-approved content.

What M11 and E6(R3) establish today

ICH adopted the final M11 guideline on November 19, 2025. Its scope covers interventional trials of medicinal products across phases and therapeutic areas. Section 1.3 explicitly separates harmonized content placement and electronic exchange from instructions for designing a sound trial. M11 does not replace other guidance governing protocol content. ICH M11 final guideline, sections 1.2–1.3

FDA issued its final M11 guidance package in May 2026, comprising a guideline, template, and technical specification. These are distinct deliverables: an M11-looking document does not demonstrate implementation of the technical specification for exchanging structured information. Ask which deliverable and revision a software claim refers to. FDA M11 guidance and supporting documents

For GCP, the ICH E6(R3) Principles and Annex 1 were adopted January 6, 2025; Annex 2 followed June 3, 2026. The consolidated document records further consolidation and corrections on June 16, 2026. Regional implementation dates differ: EMA lists July 23, 2025 for the Principles and Annex 1, and January 15, 2027 for Annex 2. Do not turn an ICH adoption date into an everywhere-effective date. EMA’s consolidated E6(R3), cover and document history

E6(R3) Annex 1 section 3.1 connects trial design with quality, feasibility, and consistent operational documents. The procurement implication is straightforward: assess whether the software helps your reviewers examine those relationships. Neither a template nor a “compliance” indicator establishes that a particular trial is scientifically appropriate or ready to conduct. E6(R3), Annex 1 section 3.1

The candidates in detail

Assyro: begin with the connection to regulatory operations

Assyro is our first evaluation recommendation when the purchasing problem includes document preparation, review, and submission work in the same program. Its document management offering provides the relevant entry point. The reason to include it is the connection to the broader regulatory workflow; its inclusion is not proof of a dedicated protocol engine.

Assyro’s current authority scope distinguishes FDA core functionality, which is generally available, from Health Canada beta and EMA roadmap support. Those statuses concern the regulatory platform. They do not establish that a specific clinical protocol template, structured M11 export, or automatic amendment check is available.

For this buying decision, require a demonstration using your protocol inputs and required outputs. Do not infer native Microsoft Word editing or preservation of Word review records from general document management. Similarly, structural submission validation is not evidence that an endpoint and its schedule agree.

The useful evaluation question is whether your team can keep the approved protocol, its supporting evidence, and the submission-facing version connected with less handoff work. Have the demonstrator identify the exact supported operations and the point at which another authoring tool or manual review becomes necessary.

If protocol-specific generation or automatic schedule consistency is mandatory on day one and remains unverified, Assyro has not passed that requirement. Continue with a candidate documenting the required authoring workflow while considering Assyro separately for its confirmed role. Editorial placement never closes a capability gap.

Certara CoAuthor: examine the complete Word review cycle

Certara describes CoAuthor as regulatory and medical writing software integrated with Microsoft Word. Its official page explicitly includes protocols among supported document types and describes structured content reuse, a permissions-governed content repository, and source-restricted generation. This makes it a documented candidate for protocol creation, beyond summarizing existing documents. Certara CoAuthor

The practical reason to shortlist it is a requirement to work inside Word while introducing reusable content and drafting assistance. That is a different implementation decision from moving all authors into a new structured editor. It still requires agreement on where shared content is maintained and what happens when someone edits a local copy.

Use a round-trip evaluation. Create a draft with one reused study identifier and one endpoint description. Send the file through the external review process your team actually uses, accept one authorized edit, then return it to the controlled workflow. Inspect comments, tracked changes, numbering, references, and the origin of regenerated passages.

Next, distinguish exact-text reuse from semantic consistency. Reusing a study name is a simpler task than recognizing that a changed assessment time affects a table footnote and a differently worded analysis paragraph. Ask the vendor to show both, and retain separate results.

Confirm which Word environments, user roles, repository connections, and implementation services the proposed license covers. The product page supports evaluating this workflow; it does not establish that every external collaborator or existing template will work without configuration.

Narrativa Clinical Atlas: control the boundary around generated design

Narrativa’s protocol page identifies Clinical Atlas and describes drafting from a study synopsis and reference documents. It also names separate agents for protocol design, burden, study population, and auditing, with source traceability and version tracking in the described workflow. These are vendor statements, not results from our own evaluation. Narrativa protocol authoring

Its distinguishing evaluation case is a team seeking a substantial first protocol draft from a defined input package. The design-related assistance makes source boundaries especially consequential. A proposed change to a population or assessment schedule should be recognizable as a suggestion requiring review, rather than silently becoming part of the sponsor’s agreed design.

Bring two sources that intentionally disagree: an approved synopsis and an older reference protocol. State which one governs the current study. Ask for the draft and a list of unresolved decisions. A fluent synthesis that borrows a conflicting visit schedule from the older protocol should fail your exercise even if its formatting is excellent.

Then remove the authoritative assessment time altogether. The acceptable response is a visible unresolved field or reviewer question. A plausible time inferred from prior studies does not satisfy an instruction to author only from agreed study decisions.

Before contracting, define which agents are included, which reference repositories are available to them, and how the sponsor can review or restrict their use. Ask for evidence from the protocol workflow itself; a successful CSR or patient-narrative demonstration answers a different document-generation question.

Trelice: challenge linked changes and dependent documents

Trelice describes a protocol platform built around structured M11 authoring. Its official page states that linked fields propagate changes across protocol sections and that generated dependent documents are flagged for regeneration when the protocol changes. It also describes Word and PDF export. Those claims make amendment impact the central reason to evaluate it. Trelice protocol platform

This approach deserves consideration when the team wants the protocol to function as a maintained source for related documents. The implementation tradeoff is the work of representing an existing protocol and its local exceptions in a structured model. A clean new-study example cannot answer how that migration behaves.

Bring a legacy protocol containing a schedule table, a free-text exception, and one site-specific document. Ask the vendor to show what imports into linked fields and what remains ordinary text. Change the linked endpoint field, inspect its impact preview, and check the exception independently. A useful result identifies uncovered content instead of treating every occurrence as automatically synchronized.

For a dependent document, verify the distinction between being flagged, regenerated, reviewed, and approved. Automatic generation can save a copying step, but a generated file should not be assumed ready for site use solely because its parent protocol changed.

Confirm the exact product access, supported output types, migration assistance, and recovery path if the structured representation is incomplete. The public description provides a strong reason to test linked content; it does not replace inspection of your own amendment and export record.

TransCelerate CPT: retain a meaningful baseline

TransCelerate’s 2026 release aligns CPT V11 Basic Word edition with the finalized M11 template and technical specifications. Its resource page says V11 updates apply only to Basic Word; the technology-enabled eTemplates remain at Release 10, with no further development planned. Do not treat every TransCelerate template edition as the same current implementation. TransCelerate Clinical Content & Reuse resources

A controlled template workflow may be sufficient when your main gap is document structure and your team already manages sources, reviews, and change impact effectively. Use it to establish a baseline for reviewer effort. The software purchase should then solve an observed problem: locating supporting decisions, controlling repeated content, identifying impacted sections, or preserving review context.

Keep the template baseline outside the commercial-platform ranking. It is a writing resource used within a process your organization must operate, not evidence of automated consistency checking or a hosted approval system.

A protocol amendment exercise you can use in a demo

The following is a synthetic editorial consistency exercise, not a recommended trial design, endpoint, or assessment schedule. It contains no patient data. It tests whether approved information remains consistent; it does not test whether the underlying medical or statistical decisions are appropriate. No listed product has been run against it for this guide.

Use a fictional document called Protocol DEMO-01, revision A. Assign the arbitrary label Assessment Q to an endpoint assessment. Supply this source packet:

Keep C-02 withheld until the baseline check is complete. The use of letters is deliberate: the exercise concerns relationships between sections, without implying that any real timing choice is appropriate.

Where a protocol amendment also affects the IB, use the investigator-brochure software evaluation to inspect the dependent document and review decision separately.

First, establish the unchanged case

Ask the software to produce or import revision A using D-01. The synopsis, endpoint description, schedule row, and analysis overview should agree on Visit B. R-00 should remain distinguishable as older reference material. Record any transformations needed to obtain this baseline.

This is a necessary control. If the baseline already contains a mismatch, you cannot attribute the later problem specifically to amendment handling. Correct the input or import issue before proceeding, and retain the correction record.

Introduce the change and inspect a deliberately incomplete result

Apply C-02, then evaluate the following candidate output. It is a deliberately defective example written for this guide, not output attributed to a vendor:

The first two passages do not rescue the draft. The schedule and analysis overview remain inconsistent. Ask the vendor to identify each affected location, show the supporting change instruction, and demonstrate how unresolved issues prevent the document being treated as ready under your review process.

Do not accept a global replacement of “Visit B” as the correction method. Add an unrelated Assessment R that correctly remains at Visit B. The expected correction moves only Assessment Q’s relevant references to Visit C and preserves Assessment R. This checks whether the process understands the relationship or merely substitutes matching text.

Recheck the evidence after reviewer correction

For the corrected example, the four protocol locations agree on Visit C for Assessment Q; Assessment R stays at Visit B. The revised file references C-02 as the change basis. The site worksheet remains unresolved until its assigned owner determines the needed action. A complete protocol edit is not a completed downstream implementation.

Export the resulting document and reopen it outside the authoring interface. Inspect the same four locations, including table cells and footnotes. A correct in-app display with a stale exported schedule should fail the output requirement.

Finally, remove the visit designation from C-02 and leave the instruction as “update the assessment.” With no approved replacement time, the process should request clarification rather than select Visit A, B, or C. This tests ambiguous instructions as well as conflicting sources.

Record results without hiding an unknown inside a score

Use this worksheet with a medical writer, the relevant clinical or statistical reviewer, and the person responsible for document control. Assign the roles to named people before the exercise.

Mark each gate pass, fail, or unresolved. Write down whether the result came from the software alone, configuration, vendor assistance, or a manual reviewer. A combined workflow may be acceptable, but its operating cost and responsibilities should be explicit.

If automatic consistency detection is mandatory, a reviewer finding the mismatch manually does not establish that software capability. If your approved process allows manual checking, assess whether the evidence and workload are acceptable. These are different purchasing requirements, and the worksheet should preserve the distinction.

Use the AI medical-writing pilot plan to measure the review needed to reach the accepted protocol output.

Choose a pilot and price the actual operating model

For a small team handling protocol preparation alongside FDA submission work, begin with Assyro’s confirmed regulatory workflow and resolve protocol-specific gaps before committing. For an established Word review process, CoAuthor is the documented candidate to examine. For synopsis-driven drafting, evaluate Clinical Atlas’s source and design boundaries. For linked protocol content and dependent outputs, test Trelice’s amendment coverage with an imported document.

Consider an assumed buyer whose mandatory requirement is automatic endpoint-to-schedule impact detection. None of the documentary descriptions here is a passed acceptance result. Assyro remains unresolved on that requirement; Trelice supplies a specific linked-change claim worth testing. The decision is to run a focused demonstration, not to award either product an unsupported capability score.

Quote the same workload to shortlisted vendors: one new protocol, one amendment, the required author and reviewer roles, external review, the agreed template, source ingestion, and final exports. Ask for setup, template mapping, training, migration, support, and any separately licensed agents or connectors to be itemized. Named prices are omitted because this guide does not establish comparable commercial terms.

Also agree how you leave. Request an export of the protocol, source inventory, version history, review decisions, and dependent-document status in the formats your organization needs. If some context can only remain inside the product, decide how it will be retained and accessed before purchase.

Bring the synthetic exercise to an Assyro workflow discussion or your shortlisted vendor, replacing its fictional inputs with permitted representative material when appropriate. Ask for the current supported scope and keep the demonstrated evidence with the proposal. Choose the workflow that can preserve approved decisions through revision and handoff with responsibilities your team can actually sustain.

Discuss the exact protocol task through Assyro’s regulatory-writing overview, subject to the document-specific evidence required here.

For a wider IND drafting purchase, the AI IND authoring checklist keeps protocol work separate from other required sections and format gates.